$CLDX Cowen and Company Reiterates Outperform Rating for Celldex Therapeutics, Inc. (CLDX)
March 10th, 2016 - By Thomas Dobrow - 0 comments
Celldex Therapeutics logoCelldex Therapeutics, Inc. (NASDAQ:CLDX)‘s stock had its “outperform” rating reiterated by research analysts at Cowen and Company in a note issued to investors on Tuesday, AnalystRatingsNetwork.com reports. They currently have a $12.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $28.00. Cowen and Company’s price target suggests a potential upside of 231.49% from the company’s current price.
Celldex Therapeutics (NASDAQ:CLDX) traded up 1.66% on Tuesday, reaching $3.68. The company’s stock had a trading volume of 1,690,793 shares. Celldex Therapeutics has a 12 month low of $3.45 and a 12 month high of $32.82. The company’s market cap is $363.23 million. The stock’s 50 day moving average price is $7.64 and its 200 day moving average price is $12.52.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.02. The firm had revenue of $1.80 million for the quarter, compared to analyst estimates of $0.80 million. The firm’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.36) earnings per share. Equities research analysts forecast that Celldex Therapeutics will post ($1.33) earnings per share for the current year.
A number of hedge funds recently bought and sold shares of CLDX. DekaBank Deutsche Girozentrale increased its stake in Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock worth $808,000 after buying an additional 500 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Celldex Therapeutics by 1.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 64,690 shares of the biopharmaceutical company’s stock worth $1,015,000 after buying an additional 662 shares during the last quarter. California State Teachers Retirement System increased its stake in Celldex Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 182,509 shares of the biopharmaceutical company’s stock worth $2,862,000 after buying an additional 2,946 shares during the last quarter. Rhumbline Advisers increased its stake in Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock worth $1,700,000 after buying an additional 5,110 shares during the last quarter. Finally, Bedell Frazier Investment Counseling LLC boosted its stake in shares of Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares during the period.
CLDX has been the subject of several other reports. Wedbush downgraded shares of Celldex Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 price objective for the company. in a research report on Monday. Cantor Fitzgerald lowered their price target on shares of Celldex Therapeutics from $31.00 to $25.00 and set a “buy” rating for the company in a report on Friday, February 26th. Brean Capital reiterated a “buy” rating and set a $31.00 price target on shares of Celldex Therapeutics in a report on Monday, November 9th. Leerink Swann downgraded shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $30.00 to $4.00 in a report on Monday. Finally, Zacks Investment Research downgraded shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 4th. Seven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $20.70.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
March 10th, 2016 - By Thomas Dobrow - 0 comments
Celldex Therapeutics logoCelldex Therapeutics, Inc. (NASDAQ:CLDX)‘s stock had its “outperform” rating reiterated by research analysts at Cowen and Company in a note issued to investors on Tuesday, AnalystRatingsNetwork.com reports. They currently have a $12.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $28.00. Cowen and Company’s price target suggests a potential upside of 231.49% from the company’s current price.
Celldex Therapeutics (NASDAQ:CLDX) traded up 1.66% on Tuesday, reaching $3.68. The company’s stock had a trading volume of 1,690,793 shares. Celldex Therapeutics has a 12 month low of $3.45 and a 12 month high of $32.82. The company’s market cap is $363.23 million. The stock’s 50 day moving average price is $7.64 and its 200 day moving average price is $12.52.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.02. The firm had revenue of $1.80 million for the quarter, compared to analyst estimates of $0.80 million. The firm’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.36) earnings per share. Equities research analysts forecast that Celldex Therapeutics will post ($1.33) earnings per share for the current year.
A number of hedge funds recently bought and sold shares of CLDX. DekaBank Deutsche Girozentrale increased its stake in Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock worth $808,000 after buying an additional 500 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Celldex Therapeutics by 1.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 64,690 shares of the biopharmaceutical company’s stock worth $1,015,000 after buying an additional 662 shares during the last quarter. California State Teachers Retirement System increased its stake in Celldex Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 182,509 shares of the biopharmaceutical company’s stock worth $2,862,000 after buying an additional 2,946 shares during the last quarter. Rhumbline Advisers increased its stake in Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock worth $1,700,000 after buying an additional 5,110 shares during the last quarter. Finally, Bedell Frazier Investment Counseling LLC boosted its stake in shares of Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares during the period.
CLDX has been the subject of several other reports. Wedbush downgraded shares of Celldex Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 price objective for the company. in a research report on Monday. Cantor Fitzgerald lowered their price target on shares of Celldex Therapeutics from $31.00 to $25.00 and set a “buy” rating for the company in a report on Friday, February 26th. Brean Capital reiterated a “buy” rating and set a $31.00 price target on shares of Celldex Therapeutics in a report on Monday, November 9th. Leerink Swann downgraded shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $30.00 to $4.00 in a report on Monday. Finally, Zacks Investment Research downgraded shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 4th. Seven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $20.70.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
